Trial Outcomes & Findings for PET-MRI in Diagnosing Patients With Colon or Rectal Cancer (NCT NCT01807117)
NCT ID: NCT01807117
Last Updated: 2021-05-18
Results Overview
SUV max in physiologic regions (blood pool, liver) and FDG avid lesions, in which the PET-CT was performed prior to the PET-MRI. SUVmax is defined as \[tissue concentration (MBq/g) x body weight (g)\]/\[injected dose (MBq/g)\]
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
15 participants
Primary outcome timeframe
Up to 6 months (each scan taking an average of 45 minutes)
Results posted on
2021-05-18
Participant Flow
Participant milestones
| Measure |
Diagnostic (PET-CT and PET-MRI)
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|
|
Overall Study
STARTED
|
15
|
|
Overall Study
COMPLETED
|
12
|
|
Overall Study
NOT COMPLETED
|
3
|
Reasons for withdrawal
| Measure |
Diagnostic (PET-CT and PET-MRI)
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|
|
Overall Study
Physician Decision
|
2
|
|
Overall Study
Disease diagnosis not a study disease
|
1
|
Baseline Characteristics
PET-MRI in Diagnosing Patients With Colon or Rectal Cancer
Baseline characteristics by cohort
| Measure |
Diagnostic (PET-CT and PET-MRI)
n=15 Participants
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|
|
Age, Customized
years · 20-29
|
0 Participants
n=5 Participants
|
|
Age, Customized
years · 30-39
|
0 Participants
n=5 Participants
|
|
Age, Customized
years · 40-49
|
4 Participants
n=5 Participants
|
|
Age, Customized
years · 50-59
|
3 Participants
n=5 Participants
|
|
Age, Customized
years · 60-69
|
4 Participants
n=5 Participants
|
|
Age, Customized
years · 70-79
|
4 Participants
n=5 Participants
|
|
Age, Customized
years · 80-89
|
0 Participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
12 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
2 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
13 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
3 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
8 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
3 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
15 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)Population: Participants who received PET-CT as initial imaging followed by PET-MRI. Evaluable lesions for this group.
SUV max in physiologic regions (blood pool, liver) and FDG avid lesions, in which the PET-CT was performed prior to the PET-MRI. SUVmax is defined as \[tissue concentration (MBq/g) x body weight (g)\]/\[injected dose (MBq/g)\]
Outcome measures
| Measure |
Blood Pool
n=23 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
Liver
n=23 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|---|
|
Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and Fluorodeoxyglucose (FDG) Avid Lesions in Participants Where PET-CT Was Performed Prior to the PET-MRI
PET-CT
|
1.9 SUV max
Interval 1.2 to 2.5
|
2.3 SUV max
Interval 1.7 to 3.4
|
|
Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and Fluorodeoxyglucose (FDG) Avid Lesions in Participants Where PET-CT Was Performed Prior to the PET-MRI
PET-MRI
|
1.3 SUV max
Interval 0.8 to 1.6
|
2.1 SUV max
Interval 1.6 to 3.4
|
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)Population: Participants who received PET-MRI was performed prior to the PET-CT. Evaluable lesions for this group.
SUV max in physiologic regions (blood pool, liver) and FDG avid lesions, in which the PET-MRI was performed prior to the PET-CT. SUVmax is defined as \[tissue concentration (MBq/g) x body weight (g)\]/\[injected dose (MBq/g)\]
Outcome measures
Outcome data not reported
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)Population: Participants who received PET-CT as initial imaging followed by PET-MRI. Evaluable lesions for this group.
SUVmax in FDG avid lesions in which the PET/CT was performed prior to the PET-MRI. SUVmax is defined as \[tissue concentration (MBq/g) x body weight (g)\]/\[injected dose (MBq/g)\]
Outcome measures
| Measure |
Blood Pool
n=16 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
Liver
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|---|
|
SUVmax in Which the PET-CT Was Performed Prior to the PET-MRI.
PET-CT
|
3.0 SUV max
Interval 0.5 to 25.5
|
—
|
|
SUVmax in Which the PET-CT Was Performed Prior to the PET-MRI.
PET-MRI
|
3.9 SUV max
Interval 1.6 to 21.6
|
—
|
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)Population: Participants who received PET-MRI as initial imaging followed by PET-CT. Evaluable lesions for this group.
SUVmax in FDG avid lesions in which the PET-MRI was performed prior to the PET-CT SUVmax is defined as \[tissue concentration (MBq/g) x body weight (g)\]/\[injected dose (MBq/g)\]
Outcome measures
| Measure |
Blood Pool
n=7 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
Liver
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|---|
|
SUVmax in Which the PET-MRI Was Performed Prior to the PET-CT
PET-CT
|
5.9 SUV max
Interval 3.4 to 8.0
|
—
|
|
SUVmax in Which the PET-MRI Was Performed Prior to the PET-CT
PET-MRI
|
4.3 SUV max
Interval 2.3 to 6.3
|
—
|
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)Population: Participants who received PET-CT as initial imaging followed by PET-MRI. Evaluable lesions for this group.
SUVmax ratio in FDG avid lesions in which the PET-CT was performed prior to the PET-MRI SUVmax is defined as \[tissue concentration (MBq/g) x body weight (g)\]/\[injected dose (MBq/g)\]
Outcome measures
| Measure |
Blood Pool
n=16 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
Liver
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|---|
|
SUVmax Ratio in Which the PET-CT Was Performed Prior to the PET-MRI
PET-CT
|
2.0 SUV max ratio
Interval 0.2 to 11.1
|
—
|
|
SUVmax Ratio in Which the PET-CT Was Performed Prior to the PET-MRI
PET-MRI
|
2.5 SUV max ratio
Interval 0.8 to 10.8
|
—
|
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)Population: Participants who received PET-MRI as initial imaging followed by PET-CT. Evaluable lesions for this group.
SUVmax ratio in FDG avid lesions in which the PET-MRI was performed prior to the PET-CT SUVmax is defined as \[tissue concentration (MBq/g) x body weight (g)\]/\[injected dose (MBq/g)\]
Outcome measures
| Measure |
Blood Pool
n=7 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
Liver
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|---|
|
SUVmax Ratio in Which the PET-MRI Was Performed Prior to the PET-CT
PET-CT
|
2.7 SUV max
Interval 1.5 to 7.2
|
—
|
|
SUVmax Ratio in Which the PET-MRI Was Performed Prior to the PET-CT
PET-MRI
|
2.0 SUV max
Interval 1.2 to 7.0
|
—
|
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)Population: Evaluable lesions for this group.
True positive rate for both modalities - TP/TP+FN TP = true positives FN = False negatives
Outcome measures
| Measure |
Blood Pool
n=23 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
Liver
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|---|
|
True Positive Rate
PET-CT
|
71 percentage of true positive results
|
—
|
|
True Positive Rate
PET-MRI
|
71 percentage of true positive results
|
—
|
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)True negative rate for both modalities - TN/TN+FP TN = true negatives FP = False positives
Outcome measures
| Measure |
Blood Pool
n=23 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
Liver
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|---|
|
True Negative Rate
PET-CT
|
100 percent
|
—
|
|
True Negative Rate
PET-MRI
|
100 percent
|
—
|
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)Population: Evaluable lesions for this group.
False negative rate for both modalities - FN/FN+TP FN = False negatives TP = true positives
Outcome measures
| Measure |
Blood Pool
n=23 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
Liver
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|---|
|
False Negative Rate
PET-CT
|
29 percent
|
—
|
|
False Negative Rate
PET-MRI
|
14 percent
|
—
|
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)On a per-lesion basis, proportion of lesions identified by PET-CT that were correctly detected by PET-MRI
Outcome measures
| Measure |
Blood Pool
n=29 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
Liver
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|---|
|
Proportion of Lesions Identified by PET-CT That Were Correctly Detected by PET-MRI
|
26 Lesions
|
—
|
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)Population: Evaluable lesions for this group.
Percent of true positive rate of diagnostic accuracy.
Outcome measures
| Measure |
Blood Pool
n=23 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
Liver
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|---|
|
Positive Predictive Values for PET-CT and PET-MRI
PET-CT
|
100 Percent of true positives
|
—
|
|
Positive Predictive Values for PET-CT and PET-MRI
PET-MRI
|
100 Percent of true positives
|
—
|
PRIMARY outcome
Timeframe: Up to 6 months (each scan taking an average of 45 minutes)Population: Evaluable lesions for this group.
Percent of true negative rate of diagnostic accuracy
Outcome measures
| Measure |
Blood Pool
n=23 Lesions
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
Liver
Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
|
|---|---|---|
|
Negative Predictive Values for PET-CT and PET-MRI
PET-MRI
|
83.33 Percent of true negatives
|
—
|
|
Negative Predictive Values for PET-CT and PET-MRI
PET-CT
|
71.43 Percent of true negatives
|
—
|
Adverse Events
Diagnostic (PET-CT and PET-MRI)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 6 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Raj Paspulati
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Phone: 1-800-641-2422
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place